vs
Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and CXApp Inc. (CXAI). Click either name above to swap in a different company.
CXApp Inc. is the larger business by last-quarter revenue ($1.0M vs $862.0K, roughly 1.2× Coeptis Therapeutics Holdings, Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -544.1%, a 397.6% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
COEP vs CXAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $862.0K | $1.0M |
| Net Profit | $-1.3M | $-5.6M |
| Gross Margin | 94.8% | 86.9% |
| Operating Margin | -230.6% | -576.9% |
| Net Margin | -146.5% | -544.1% |
| Revenue YoY | — | -38.5% |
| Net Profit YoY | 55.1% | -56.7% |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $862.0K | $1.0M | ||
| Q3 25 | $237.4K | $1.1M | ||
| Q2 25 | $200.7K | $1.2M | ||
| Q1 25 | $62.9K | $1.2M | ||
| Q4 24 | $0 | $1.7M | ||
| Q3 24 | $0 | $1.9M | ||
| Q2 24 | $0 | $1.8M | ||
| Q1 24 | $0 | $1.8M |
| Q4 25 | $-1.3M | $-5.6M | ||
| Q3 25 | $-2.9M | $-3.2M | ||
| Q2 25 | $-4.3M | $-3.1M | ||
| Q1 25 | $-3.4M | $-1.6M | ||
| Q4 24 | $-2.8M | $-3.5M | ||
| Q3 24 | $-1.8M | $-5.4M | ||
| Q2 24 | $-3.0M | $-5.3M | ||
| Q1 24 | $-3.0M | $-5.2M |
| Q4 25 | 94.8% | 86.9% | ||
| Q3 25 | 81.0% | 89.0% | ||
| Q2 25 | 77.5% | 86.0% | ||
| Q1 25 | 28.2% | 87.7% | ||
| Q4 24 | — | 86.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | 80.0% | ||
| Q1 24 | — | 82.0% |
| Q4 25 | -230.6% | -576.9% | ||
| Q3 25 | -1043.2% | -343.4% | ||
| Q2 25 | -2252.9% | -336.1% | ||
| Q1 25 | -6452.6% | -306.0% | ||
| Q4 24 | — | -169.7% | ||
| Q3 24 | — | -194.3% | ||
| Q2 24 | — | -206.7% | ||
| Q1 24 | — | -197.3% |
| Q4 25 | -146.5% | -544.1% | ||
| Q3 25 | -1220.8% | -283.4% | ||
| Q2 25 | -2159.9% | -256.7% | ||
| Q1 25 | -5440.9% | -132.0% | ||
| Q4 24 | — | -213.6% | ||
| Q3 24 | — | -286.5% | ||
| Q2 24 | — | -297.6% | ||
| Q1 24 | — | -284.4% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.58 | — | ||
| Q2 25 | $-1.17 | — | ||
| Q1 25 | $-1.11 | — | ||
| Q4 24 | $-5.35 | — | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $676.6K | $11.1M |
| Total DebtLower is stronger | $150.0K | — |
| Stockholders' EquityBook value | $13.6M | $14.0M |
| Total Assets | $16.2M | $32.4M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $676.6K | $11.1M | ||
| Q3 25 | $421.7K | $5.1M | ||
| Q2 25 | $990.6K | $4.9M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $4.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | $13.6M | $14.0M | ||
| Q3 25 | $10.4M | $15.2M | ||
| Q2 25 | $6.1M | $14.3M | ||
| Q1 25 | $6.5M | $15.6M | ||
| Q4 24 | $3.4M | $15.6M | ||
| Q3 24 | $4.8M | $13.6M | ||
| Q2 24 | $-442.6K | $16.3M | ||
| Q1 24 | $-1.1M | $20.9M |
| Q4 25 | $16.2M | $32.4M | ||
| Q3 25 | $14.2M | $28.5M | ||
| Q2 25 | $12.2M | $29.6M | ||
| Q1 25 | $13.5M | $29.3M | ||
| Q4 24 | $8.9M | $31.8M | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-3.6M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -355.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-10.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.6M | $-3.6M | ||
| Q3 25 | $-2.2M | $-2.8M | ||
| Q2 25 | $-2.4M | $-3.0M | ||
| Q1 25 | $-2.4M | $-979.0K | ||
| Q4 24 | $-6.6M | $-2.7M | ||
| Q3 24 | $-1.9M | $-2.1M | ||
| Q2 24 | $-1.4M | $-1.9M | ||
| Q1 24 | $-1.9M | $-650.0K |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | $-984.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-668.0K |
| Q4 25 | — | -355.5% | ||
| Q3 25 | — | -248.1% | ||
| Q2 25 | — | -247.2% | ||
| Q1 25 | — | -80.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -109.3% | ||
| Q2 24 | — | -108.6% | ||
| Q1 24 | — | -36.7% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
